Replies to post #202497 on Biotech Values

[poorgradstudent]

lower disease burden after initial on off interval making another on cycle safer?

At first blush this sound analogous to how we make mutant / resistant strains in the lab.

If you are actually lowering disease burden, why not let the CAR-Ts persist?

Not trying to be combative or obtuse, just trying to reason out the setting where an On/Off CAR-T would be necessary.